The Blood: Part 5 | Hemostasis | Platelet Plug | Coagulation | Clotting | Fibrinolysis
RC Webinars: How to personalize NOAC for special populations and special situations
Interventional management of thrombotic risk in atrial fibrillation
חידושים בטיפול בפרפור פרוזדורים
Tecarfarin is a vitamin K antagonist under development for use as an anticoagulant. A Phase II/III clinical trial in 607 people, comparing it to the established vitamin K antagonist warfarin, found no difference in quality of anticoagulation or side effects between the two drugs in the overall population. Among patients taking CYP2C9 interacting drugs however, the tecarfarin patients’ TTR was72.2% (n=92) vs 69.9% (n=87) for warfarin patients (pint=0.16); among patients who had both a CYP2C9 variant allele and taking a CYP2C9 interacting drug, TTR was 76.5% and 69.5% for the tecarfarin (n=24) and warfarin (n=31) groups, respectively (pint=0.24). In contrast to warfarin, tecarfarin is not affected by the cytochrome P450 inhibiting drug fluconazole, indicating a lower potential for interactions with other drugs.
Explore contextually related video stories in a new eye-catching way. Try Combster now!